Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 85 results for colitis

  1. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

    Medtech innovation briefing
    Published
    12 July 2022

  2. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  3. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    27 September 2019
    View recommendations

    Sections for NG141

  5. Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal (IPG642)

    Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.

    Interventional procedures guidance
    Published
    20 February 2019
    View recommendations

    Sections for IPG642

  6. What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates?

    methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates? Any explanatory...

    Research recommendation
    Published
    25 October 2019

  7. What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition to aminosalicylates compared with each other and with aminosalicylate monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis?

    the induction of remission for people with mild-to-moderate ulcerative colitis? Any explanatory notes(if applicable) To find out why the...

    Research recommendation
    Published
    25 October 2019

  8. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  9. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

    Medtech innovation briefing
    Published
    21 July 2015

  10. What is the clinical and cost effectiveness of prednisolone plus an aminosalicylate compared with beclometasone plus an aminosalicylate for induction of remission for people with moderate ulcerative colitis?

    ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...

    Research recommendation
    Published
    25 October 2019

  11. What is the clinical and cost effectiveness of prednisolone compared with aminosalicylates for the induction of remission for people with moderate ulcerative colitis?

    ulcerative colitis? Any explanatory notes(if applicable) Source guidance details Comes from guidance Ulcerative colitis:...

    Research recommendation
    Published
    25 October 2019

  12. What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?

    placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids? Any...

    Research recommendation
    Published
    25 October 2019

  13. Evaluation of guidelines for the use of faecal calprotectin testing in primary care

    current) comparator pathway (5%). 89% of patients with IBD (ulcerative colitis; 4 patients and Crohn's disease 5) had a FC 250mcg/g and...

    Shared learning
    Last updated
    26 August 2015

  14. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 June 2018
    View quality statements

    Sections for QS170

  15. Adenoma types and risk of colorectal cancer:- Does the risk of colorectal cancer depend on the type of adenoma?

    cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued

    Research recommendation
    Published
    9 June 2015